Bavarian Nordic has appointed Tarja Stenvall as its next president and chief executive, ending a search that began in the spring. The Danish vaccine maker said Stenvall would take charge on October 15, succeeding Paul Chaplin, who has led the company for years and signaled in early March that he intended to step down.
Stenvall arrives with more than two decades in the pharmaceutical industry. She joins from Sanofi, where she served as senior vice president in charge of a diabetes and cardiovascular business worth around 10 billion euros in annual sales. Before that she held commercial leadership roles of growing scope at AstraZeneca and Pfizer, building a career centered on running large drug franchises across international markets. That commercial grounding stands out at a company whose growth now depends as much on selling its vaccines widely as on developing them.
Anne Louise Eberhard, chair of the board, said the new chief executive offered the mix of experience the company was looking for. “Tarja brings a proven ability to scale and lead a global life science business, combining strategic vision with deep pharma expertise,” Eberhard said. The board framed the appointment as a step toward turning Bavarian Nordic’s established position in vaccines into wider commercial growth.
Stenvall said the move appealed to her both as a business challenge and as a chance to work in public health. “The opportunity to join Bavarian Nordic is tremendously exciting. The company has built a leading position in vaccines while remaining committed to improving lives,” she said. She holds an economics degree from Aalto University in Finland and an MBA in international business from the University of South Carolina.
Bavarian Nordic has built its business around vaccines for governments and public agencies, including shots against mpox and smallpox, alongside a portfolio of travel vaccines. The company sits in a corner of the industry shaped by public health preparedness and outbreak response, where demand can swing sharply with events and where large government contracts can arrive or lapse with little warning. The task facing Stenvall will be to steady that base while finding new avenues for growth, and to manage the handover from a chief executive who shaped the company over a long tenure, as she takes over in the middle of October.
